Literature DB >> 30145654

NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.

Victor A D Holanda1, Wilton B Santos1, Laila Asth1, Remo Guerrini2, Girolamo Calo'3, Chiara Ruzza3, Elaine C Gavioli4.   

Abstract

RATIONALE: Nociceptin/orphanin FQ (N/OFQ) is the endogenous ligand of a Gi protein-coupled receptor named NOP. Both N/OFQ and NOP receptor are widely expressed in brain areas involved in the control of emotional processes. Clinical and preclinical studies support antidepressant effects due to the blockade of NOP receptor signaling. By contrast, NOP receptor activation did not evoke any change in behavioral despair tests.
OBJECTIVES: The present study aimed to investigate the effects of the co-administration of NOP agonists and classic antidepressant drugs in the forced swimming test (FST) and learned helplessness model (LH) in mice.
METHODS: Male Swiss mice were co-administered with NOP agonists (N/OFQ and Ro 65-6570) and antidepressants (nortriptyline, fluoxetine, and R-ketamine) or SB-612111 (NOP antagonist) and the behavioral effects were assessed in the FST and LH tests.
RESULTS: Fluoxetine, nortriptyline, R-ketamine and the NOP antagonist SB-612111 displayed antidepressant-like effects in the FST. The administration of the NOP agonists N/OFQ and Ro 65-6570 did not induce any behavioral change. However, co-administration of NOP agonists blocked the antidepressant effects of SB-612111, fluoxetine, and nortriptyline, but not R-ketamine in the FST. Similarly, in the LH, the systemic injection of SB-612111, nortriptyline, and R-ketamine reversed helplessness. The co-administration of Ro 65-6570 blocked the antidepressant-like effects of SB-612111 and nortriptyline, but not R-ketamine.
CONCLUSIONS: NOP receptor activation inhibits the acute antidepressant effects of nortriptyline and fluoxetine, but not R-ketamine. The present findings contribute to further understand the role played by the N/OFQ-NOP receptor system in regulating mood states.

Entities:  

Keywords:  Antidepressants; Forced swimming test; Learned helplessness; Mouse; NOP receptor; Nociceptin/orphanin FQ

Mesh:

Substances:

Year:  2018        PMID: 30145654     DOI: 10.1007/s00213-018-5004-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  58 in total

1.  Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffold.

Authors:  Miguel A Toledo; Concepción Pedregal; Celia Lafuente; Nuria Diaz; Maria Angeles Martinez-Grau; Alma Jiménez; Ana Benito; Alicia Torrado; Carlos Mateos; Elizabeth M Joshi; Steven D Kahl; Karen S Rash; Daniel R Mudra; Vanessa N Barth; David B Shaw; David McKinzie; Jeffrey M Witkin; Michael A Statnick
Journal:  J Med Chem       Date:  2014-04-11       Impact factor: 7.446

2.  Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.

Authors:  Celia Goeldner; Will Spooren; Jürgen Wichmann; Eric P Prinssen
Journal:  Psychopharmacology (Berl)       Date:  2012-01-18       Impact factor: 4.530

3.  Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat.

Authors:  C R Neal; A Mansour; R Reinscheid; H P Nothacker; O Civelli; S J Watson
Journal:  J Comp Neurol       Date:  1999-04-19       Impact factor: 3.215

4.  Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice.

Authors:  Tomasz Kos; Beata Legutko; Wojciech Danysz; Gary Samoriski; Piotr Popik
Journal:  J Pharmacol Exp Ther       Date:  2006-06-01       Impact factor: 4.030

5.  Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice.

Authors:  E C Gavioli; C W Vaughan; G Marzola; R Guerrini; V A Mitchell; S Zucchini; T C M De Lima; G A Rae; S Salvadori; D Regoli; G Calo'
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-05-25       Impact factor: 3.000

6.  Nociceptin/orphanin FQ decreases serotonin efflux in the rat brain but in contrast to a kappa-opioid has no antagonistic effect on mu-opioid-induced increases in serotonin efflux.

Authors:  R Tao; Z Ma; M M Thakkar; R W McCarley; S B Auerbach
Journal:  Neuroscience       Date:  2007-05-14       Impact factor: 3.590

7.  Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness.

Authors:  Victor A D Holanda; Iris U Medeiros; Laila Asth; Remo Guerrini; Girolamo Calo'; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2016-04-30       Impact factor: 4.530

8.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

9.  Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors.

Authors:  Jeffrey M Witkin; Linda M Rorick-Kehn; Mark J Benvenga; Benjamin L Adams; Scott D Gleason; Karen M Knitowski; Xia Li; Steven Chaney; Julie F Falcone; Janice W Smith; Julie Foss; Kirsti Lloyd; John T Catlow; David L McKinzie; Kjell A Svensson; Vanessa N Barth; Miguel A Toledo; Nuria Diaz; Celia Lafuente; Alma Jiménez; Alfonso Benito; Conception Pedregal; Maria A Martínez-Grau; Anke Post; Michael A Ansonoff; John E Pintar; Michael A Statnick
Journal:  Pharmacol Res Perspect       Date:  2016-11-07

10.  S-Ketamine Mediates Its Acute and Sustained Antidepressant-Like Activity through a 5-HT1B Receptor Dependent Mechanism in a Genetic Rat Model of Depression.

Authors:  Kristian G du Jardin; Nico Liebenberg; Manuel Cajina; Heidi K Müller; Betina Elfving; Connie Sanchez; Gregers Wegener
Journal:  Front Pharmacol       Date:  2018-01-15       Impact factor: 5.810

View more
  6 in total

1.  Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress.

Authors:  Aldemara I Silva; Victor A D Holanda; Joaquim G Azevedo Neto; Edilson D Silva Junior; Vanessa P Soares-Rachetti; Girolamo Calo; Chiara Ruzza; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2020-02-24       Impact factor: 4.530

Review 2.  The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies.

Authors:  Lawrence Toll; Andrea Cippitelli; Akihiko Ozawa
Journal:  CNS Drugs       Date:  2021-05-31       Impact factor: 6.497

Review 3.  Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists.

Authors:  Jong Yung Park; Suji Chae; Chang Seop Kim; Yoon Jae Kim; Hyun Joo Yi; Eunjoo Han; Youngshin Joo; Surim Hong; Jae Won Yun; Hyojung Kim; Kyung Ho Shin
Journal:  Korean J Physiol Pharmacol       Date:  2019-10-24       Impact factor: 2.016

4.  Blockade of nociceptin/orphanin FQ signaling facilitates an active copying strategy due to acute and repeated stressful stimuli in mice.

Authors:  Victor A D Holanda; Matheus C Oliveira; Edilson D Da Silva Junior; Girolamo Calo'; Chiara Ruzza; Elaine C Gavioli
Journal:  Neurobiol Stress       Date:  2020-10-05

Review 5.  A systematic review of studies investigating the acute effects of N-methyl-D-aspartate receptor antagonists on behavioural despair in normal animals suggests poor predictive validity.

Authors:  Martin Viktorov; Matthew P Wilkinson; Victoria C E Elston; Medi Stone; Emma S J Robinson
Journal:  Brain Neurosci Adv       Date:  2022-03-12

Review 6.  Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders.

Authors:  Massimo Ubaldi; Nazzareno Cannella; Anna Maria Borruto; Michele Petrella; Maria Vittoria Micioni Di Bonaventura; Laura Soverchia; Serena Stopponi; Friedbert Weiss; Carlo Cifani; Roberto Ciccocioppo
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.